$ZEOX
Zeo ScientifiX, Inc. Stock $zeox

$zeox Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000182912624006296 Filed on September 16, 2024

Income Statement

Concept	2024 Q3
Revenue	$1.091M
YoY Change	-10.62%
Cost Of Revenue	$176.0K
YoY Change	8.42%
Gross Profit	$915.0K
YoY Change	-13.54%
Gross Profit Margin	83.87%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$75.00K
YoY Change	-77.59%
% of Gross Profit	8.2%
Depreciation & Amortization	$18.00K
YoY Change	-42.38%
% of Gross Profit	1.97%
Operating Expenses	$75.00K
YoY Change	-77.59%
Operating Profit	-$1.168M
YoY Change	-19.25%
Interest Expense	$23.00K
YoY Change	-86.58%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$1.012M
YoY Change	-37.44%
Net Earnings / Revenue	-92.76%
Basic Earnings Per Share	-$0.16
Diluted Earnings Per Share	-$0.16
COMMON SHARES
Basic Shares Outstanding	6.260M shares
Diluted Shares Outstanding	6.260M shares

Balance Sheet

Concept	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$1.105M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$250.0K
Prepaid Expenses	$339.0K
Receivables	$19.00K
Other Receivables	$12.00K
Total Short-Term Assets	$1.725M
YoY Change	59.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$496.0K
YoY Change	-58.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$496.0K
YoY Change	-63.99%
TOTAL ASSETS
Total Short-Term Assets	$1.725M
Total Long-Term Assets	$496.0K
Total Assets	$2.221M
YoY Change	-9.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due	$674.0K
YoY Change	44.0%
Total Short-Term Liabilities	$3.634M
YoY Change	9.59%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.634M
Total Long-Term Liabilities
Total Liabilities	$3.643M
YoY Change	4.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$60.96M
YoY Change	8.05%
Common Stock	$6.000K
YoY Change	-99.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.422M
YoY Change
Total Liabilities & Shareholders Equity	$2.221M
YoY Change	-9.56%

Cashflow Statement

Concept	2024 Q3
OPERATING ACTIVITIES
Net Income	-$1.012M
YoY Change	-37.44%
Depreciation, Depletion And Amortization	$18.00K
YoY Change	-42.38%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--10-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001557376
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-07-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-55008
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4180540
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3321 College Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 246
	dei	Entity Address City Or Town EntityAddressCityOrTown	Davie
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33314
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	68000	usd
CY2023Q3	ZEOX	Revenues From Related Parties RevenuesFromRelatedParties	43000	usd
	ZEOX	Revenues From Related Parties RevenuesFromRelatedParties	117000	usd
	ZEOX	Revenues From Related Parties RevenuesFromRelatedParties	151000	usd
	us-gaap	Revenues Revenues	3376000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	375000	usd
	us-gaap	Gross Profit GrossProfit	2757000	usd
	us-gaap	Gross Profit GrossProfit	2761000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6651000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8297000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3894000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5536000	usd
	us-gaap	Interest Expense InterestExpense	70000	usd
	us-gaap	Interest Expense InterestExpense	341000	usd
CY2024Q3	us-gaap	Security Deposit SecurityDeposit		usd
CY2024Q3	ZEOX	Advances Payable To Former Officer AdvancesPayableToFormerOfficer		usd
CY2023Q3	ZEOX	Writeoff Of Advances Payable To Former Officer WriteoffOfAdvancesPayableToFormerOfficer		usd
	ZEOX	Writeoff Of Advances Payable To Former Officer WriteoffOfAdvancesPayableToFormerOfficer		usd
CY2024Q3	ZEOX	Resolution And Settlement Of Long Outstanding Payables ResolutionAndSettlementOfLongOutstandingPayables		usd
CY2023Q3	ZEOX	Resolution And Settlement Of Long Outstanding Payables ResolutionAndSettlementOfLongOutstandingPayables		usd
	ZEOX	Resolution And Settlement Of Long Outstanding Payables ResolutionAndSettlementOfLongOutstandingPayables		usd
CY2023Q3	ZEOX	Reserve Of Nonmarketable Securities ReserveOfNonmarketableSecurities		usd
	ZEOX	Reserve Of Nonmarketable Securities ReserveOfNonmarketableSecurities		usd
CY2024Q3	ZEOX	Commissions On Sales Of Formulator Products CommissionsOnSalesOfFormulatorProducts		usd
CY2023Q3	ZEOX	Commissions On Sales Of Formulator Products CommissionsOnSalesOfFormulatorProducts		usd
	ZEOX	Commissions On Sales Of Formulator Products CommissionsOnSalesOfFormulatorProducts		usd
CY2024Q3	ZEOX	Proceeds From Insurance Claim ProceedsFromInsuranceClaim		usd
CY2023Q3	ZEOX	Proceeds From Insurance Claim ProceedsFromInsuranceClaim		usd
	ZEOX	Proceeds From Insurance Claim ProceedsFromInsuranceClaim		usd
CY2023Q3	us-gaap	Other Income OtherIncome		usd
	us-gaap	Other Income OtherIncome		usd
CY2024Q3	ZEOX	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation		usd
CY2023Q3	ZEOX	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation		usd
	ZEOX	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation		usd
CY2023Q3	ZEOX	Fair Value Of Vested Shares Issued FairValueOfVestedSharesIssued		usd
CY2023Q3	ZEOX	Return Of Former Executives Shares And Warrants ReturnOfFormerExecutivesSharesAndWarrants		usd
	ZEOX	Cancellation Of Shares Repurchased In Connection With Litigation CancellationOfSharesRepurchasedInConnectionWithLitigation		usd
	ZEOX	Return Of Former Executives Shares And Warrants ReturnOfFormerExecutivesSharesAndWarrants		usd
	ZEOX	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
	ZEOX	Cancellation Of Shares In Connection With Litigation CancellationOfSharesInConnectionWithLitigation		usd
	ZEOX	Change In Commitments Fee Shortfall Obligation ChangeInCommitmentsFeeShortfallObligation		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost		usd
	ZEOX	Writeoff Of Advances Payable To Former Officer WriteoffOfAdvancesPayableToFormerOfficer		usd
	ZEOX	Reserve Of Nonmarketable Securities Related Party ReserveOfNonmarketableSecuritiesRelatedParty		usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	ZEOX	Shares Repurchased In Connection With Litigation SharesRepurchasedInConnectionWithLitigation		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	ZEOX	Reduction In Accounts Payable For Equipment Returned To Vendor ReductionInAccountsPayableForEquipmentReturnedToVendor		usd
	ZEOX	Exchange Of Shares For Payables ExchangeOfSharesForPayables		usd
	ZEOX	Oid Discount On Proceeds Received From Promissory Notes OidDiscountOnProceedsReceivedFromPromissoryNotes		usd
	ZEOX	Common Stock And Warrants Issued As Commitment Fee For Promissory Notes CommonStockAndWarrantsIssuedAsCommitmentFeeForPromissoryNotes		usd
	ZEOX	Common Stock Issued In Satisfaction Of Commitment Fee Shortfall Obligation CommonStockIssuedInSatisfactionOfCommitmentFeeShortfallObligation		usd
CY2024Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent		usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent		usd
CY2024Q3	ZEOX	Accrued Irs Penalty AccruedIrsPenalty		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares		shares
CY2023Q4	ZEOX	Fair Value Of Nonvested Shares FairValueOfNonvestedShares		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares		shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
	ZEOX	Fair Value Of Expiredforfeited Shares FairValueOfExpiredforfeitedShares		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q4	ZEOX	Initial Purchase Order InitialPurchaseOrder		usd
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	Zeo ScientifiX, Inc.
	dei	City Area Code CityAreaCode	888
	dei	Local Phone Number LocalPhoneNumber	963-7881
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6582419	shares
CY2024Q3	us-gaap	Cash Cash	1105000	usd
CY2023Q4	us-gaap	Cash Cash	1756000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18000	usd
CY2024Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	12000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	12000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	339000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	106000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	250000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	310000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	1725000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2202000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	496000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	573000	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	7000	usd
CY2024Q3	us-gaap	Assets Assets	2221000	usd
CY2023Q4	us-gaap	Assets Assets	2782000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1850000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2612000	usd
CY2023Q4	ZEOX	Advances Payable To Former Officer AdvancesPayableToFormerOfficer	221000	usd
CY2024Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	5000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	23000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	51000	usd
CY2024Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	674000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	657000	usd
CY2024Q3	us-gaap	Deferred Revenue DeferredRevenue	1105000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	497000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3634000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4010000	usd
CY2024Q3	ZEOX	Long Term Finance Lease Obligations LongTermFinanceLeaseObligations	9000	usd
CY2023Q4	ZEOX	Long Term Finance Lease Obligations LongTermFinanceLeaseObligations	13000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	3643000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4023000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6582419	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6582419	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7283483	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7283483	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	59531000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	56260000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60959000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57508000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-1422000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1241000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2221000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2782000	usd
CY2024Q3	ZEOX	Revenues From Related Parties RevenuesFromRelatedParties	35000	usd
CY2024Q3	us-gaap	Revenues Revenues	1091000	usd
CY2023Q3	us-gaap	Revenues Revenues	1221000	usd
	us-gaap	Revenues Revenues	3136000	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	176000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	162000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	619000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	915000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	1059000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2083000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2505000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1168000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1446000	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	23000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	172000	usd
CY2024Q3	ZEOX	Writeoff Of Advances Payable To Former Officer WriteoffOfAdvancesPayableToFormerOfficer	221000	usd
	ZEOX	Writeoff Of Advances Payable To Former Officer WriteoffOfAdvancesPayableToFormerOfficer	221000	usd
	ZEOX	Resolution And Settlement Of Long Outstanding Payables ResolutionAndSettlementOfLongOutstandingPayables	154000	usd
CY2024Q3	ZEOX	Reserve Of Nonmarketable Securities ReserveOfNonmarketableSecurities	45000	usd
	ZEOX	Reserve Of Nonmarketable Securities ReserveOfNonmarketableSecurities	45000	usd
	ZEOX	Commissions On Sales Of Formulator Products CommissionsOnSalesOfFormulatorProducts	87000	usd
	ZEOX	Proceeds From Insurance Claim ProceedsFromInsuranceClaim	89000	usd
CY2024Q3	us-gaap	Other Income OtherIncome	3000	usd
	us-gaap	Other Income OtherIncome	7000	usd
	ZEOX	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation	19000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1012000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1618000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3451000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5896000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6259975	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6259975	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7103521	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7103521	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6254652	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6254652	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7027005	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7027005	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-139000	usd
CY2023Q3	ZEOX	Fair Value Of Vested Options And Warrants Issued FairValueOfVestedOptionsAndWarrantsIssued	735000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1618000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1022000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1700000	usd
CY2024Q3	ZEOX	Sale Of Common Stock Value SaleOfCommonStockValue	500000	usd
CY2024Q3	ZEOX	Fair Value Of Vested Shares Issued FairValueOfVestedSharesIssued	31000	usd
CY2024Q3	ZEOX	Fair Value Of Vested Options And Warrants Issued FairValueOfVestedOptionsAndWarrantsIssued	759000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-1012000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-1422000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1889000	usd
	ZEOX	Sale Of Common Stock Value SaleOfCommonStockValue	100000	usd
	ZEOX	Fair Value Of Vested Shares Issued FairValueOfVestedSharesIssued	452000	usd
	ZEOX	Fair Value Of Vested Options And Warrants Issued FairValueOfVestedOptionsAndWarrantsIssued	1958000	usd
	ZEOX	Issuance Of Common Stock And Warrants As Commitment Fee For Spa23 Note IssuanceOfCommonStockAndWarrantsAsCommitmentFeeForSpa23Note	282000	usd
	ZEOX	Stock Issued In Satisfaction Of Commitment Fee Shortfall Obligation StockIssuedInSatisfactionOfCommitmentFeeShortfallObligation	193000	usd
	us-gaap	Profit Loss ProfitLoss	-5896000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1022000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1241000	usd
	ZEOX	Sale Of Common Stock Value SaleOfCommonStockValue	500000	usd
	ZEOX	Exchange Of Accounts Payable For Stock ExchangeOfAccountsPayableForStock	20000	usd
	ZEOX	Fair Value Of Vested Shares Issued FairValueOfVestedSharesIssued	418000	usd
	ZEOX	Fair Value Of Vested Options And Warrants Issued FairValueOfVestedOptionsAndWarrantsIssued	2332000	usd
	us-gaap	Profit Loss ProfitLoss	-3451000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-1422000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3451000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5896000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	56000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	470000	usd
	ZEOX	Amortization Of Oid And Commitment Fee Discount Promissory Notes AmortizationOfOidAndCommitmentFeeDiscountPromissoryNotes	18000	usd
	ZEOX	Amortization Of Oid And Commitment Fee Discount Promissory Notes AmortizationOfOidAndCommitmentFeeDiscountPromissoryNotes	283000	usd
	ZEOX	Change In Commitments Fee Shortfall Obligation ChangeInCommitmentsFeeShortfallObligation	19000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-33000	usd
	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	129000	usd
	ZEOX	Writeoff Of Advances Payable To Former Officer WriteoffOfAdvancesPayableToFormerOfficer	221000	usd
	ZEOX	Reserve Of Nonmarketable Securities Related Party ReserveOfNonmarketableSecuritiesRelatedParty	45000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2751000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2410000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-34000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	14000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	233000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-29000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-60000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-721000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	49000	usd
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	7000	usd
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	12000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	607000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	33000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1084000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2418000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20000	usd
	ZEOX	Investment In Nonmarketable Equity Securities Related Party InvestmentInNonmarketableEquitySecuritiesRelatedParty	45000	usd
	ZEOX	Investment In Nonmarketable Equity Securities Related Party InvestmentInNonmarketableEquitySecuritiesRelatedParty	100000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-45000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-120000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	504000	usd
	ZEOX	Shares Repurchased In Connection With Litigation SharesRepurchasedInConnectionWithLitigation	500000	usd
	ZEOX	Payments On Finance Lease PaymentsOnFinanceLease	22000	usd
	ZEOX	Payments On Finance Lease PaymentsOnFinanceLease	86000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	600000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	500000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	478000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-582000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-651000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3120000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1756000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3753000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1105000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	633000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3000	usd
	us-gaap	Interest Paid Net InterestPaidNet	54000	usd
	ZEOX	Reduction In Accounts Payable For Equipment Returned To Vendor ReductionInAccountsPayableForEquipmentReturnedToVendor	21000	usd
	ZEOX	Exchange Of Shares For Payables ExchangeOfSharesForPayables	20000	usd
	ZEOX	Oid Discount On Proceeds Received From Promissory Notes OidDiscountOnProceedsReceivedFromPromissoryNotes	11000	usd
	ZEOX	Common Stock And Warrants Issued As Commitment Fee For Promissory Notes CommonStockAndWarrantsIssuedAsCommitmentFeeForPromissoryNotes	283000	usd
	ZEOX	Common Stock Issued In Satisfaction Of Commitment Fee Shortfall Obligation CommonStockIssuedInSatisfactionOfCommitmentFeeShortfallObligation	193000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_809_eus-gaap--NatureOfOperations_z2AxMZsEzyOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 – <span id="xdx_824_zYcrd7NZYQj7">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Zeo ScientifiX, Inc. (“ZEO” or the “Company”) (f/k/a Organicell Regenerative Medicine, Inc.) was incorporated on August 9, 2011 in the State of Nevada under the name Bespoke Tricycles Inc. (changed to Biotech Products Services and Research, Inc. during September 2015 and to Organicell Regenerative Medicine, Inc., effective June 20, 2018). Effective February 20, 2024, we further amended our Articles of Incorporation to assume our current name, Zeo ScientifiX, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company’s proprietary products, including Zofin™, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X™ (“PPX™”), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood (“RAAM Products”). Our RAAM Products and related services are principally used in the health care industry administered through doctors and clinics (“Providers”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the nine months ended July 31, 2024 and 2023, the Company principally operated through General Surgical of Florida, Inc., a Florida corporation and wholly owned subsidiary, which was formed to sell the Company’s therapeutic products to Providers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is currently exploring the use of its proprietary products in future formulations for a variety of topical use applications in the skin-care industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective November 28, 2023, we implemented a one-for-200 reverse stock split (the “Reverse Split”). The par value of the Company’s common stock was unchanged at $0.001 per share after the Reverse Split. As a result, on the effective date of the Reverse Split, the stated capital on the Company’s balance sheet attributable to the Company’s common stock was reduced proportionately based on the Reverse Split ratio of one-for-200 and the additional paid-in capital account was credited with the amount by which the stated capital was reduced. All share and per share amounts referenced herein give effect to the Reverse Split as of the earliest period presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zhEZdHEzXhQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86A_zPf7xwyGTvT9">Concentrations of Risk</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Credit Risk</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_c20240731_pp0p0" title="FDIC limits per institutions">250,000</span> per institution. At July 31, 2024, the Company held a total of approximately $<span id="xdx_90E_eus-gaap--CashUninsuredAmount_c20240731_pp0p0" title="Cash balances">343,000</span> of cash balances in two financial institutions in excess of FDIC insurance coverage limits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Major Customer</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended July 31, 2024, the Company sold products and services totaling approximately $<span id="xdx_907_eus-gaap--Revenues_c20240501__20240731__srt--MajorCustomersAxis__custom--LargeDistributorMember_pp0p0" title="Revenues">178,000</span> (<span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_c20240501__20240731__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_pdd" title="Concentration percentage">16.3%</span>) to a large distributor. During the three months ended July 31, 2023, the Company sold products and services totaling approximately $<span id="xdx_909_eus-gaap--Revenues_c20230501__20230731__srt--MajorCustomersAxis__custom--LargeDistributorMember_pp0p0" title="Revenues">334,000</span> (<span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_c20230501__20230731__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_pdd" title="Concentration percentage">27.3%</span>) to a large distributor and approximately $<span id="xdx_90C_eus-gaap--Revenues_c20240501__20240731__srt--MajorCustomersAxis__custom--IndividualMedicalPracticeMember_pp0p0" title="Revenues">125,000</span> (<span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_c20240501__20240731__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--IndividualMedicalPracticeMember_pdd" title="Concentration percentage">10.2%</span>) to an individual medical practice.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended July 31, 2024, the Company sold products and services totaling approximately $<span id="xdx_90B_eus-gaap--Revenues_c20231101__20240731__srt--MajorCustomersAxis__custom--LargeDistributorMember_pp0p0" title="Revenues">570,000</span> (<span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_c20231101__20240731__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_pdd" title="Concentration percentage">16.8%</span>) to a large distributor, approximately $<span id="xdx_906_eus-gaap--Revenues_c20231101__20240731__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pp0p0" title="Revenues">418,000</span> (<span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_c20231101__20240731__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pdd" title="Concentration percentage">12.3%</span>) to another large distributor and approximately $<span id="xdx_908_eus-gaap--Revenues_c20231101__20240731__srt--MajorCustomersAxis__custom--IndividualMedicalPracticeMember_pp0p0" title="Revenues">382,000</span> (<span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_c20231101__20240731__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--IndividualMedicalPracticeMember_pdd" title="Concentration percentage">11.2%</span>) to an individual medical practice. During the nine months ended July 31, 2023, the Company sold a total of approximately $<span id="xdx_90D_eus-gaap--Revenues_c20221101__20230731__srt--MajorCustomersAxis__custom--LargeDistributorMember_pp0p0" title="Revenues">880,000</span> (<span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_c20221101__20230731__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_pdd" title="Concentration percentage">28.1%</span>) to a large distributor and approximately $<span id="xdx_900_eus-gaap--Revenues_c20221101__20230731__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pp0p0" title="Revenues">448,000 </span>(<span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_c20221101__20230731__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pdd" title="Concentration percentage">14.3%</span>) to another large distributor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s sales agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	343000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zoDh0ndU8TUl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_866_zQGEkkzZsx3l">Use of Estimates</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term tangible and intangible assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services, and assumptions used in the determination of the Company’s liquidity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	75000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	335000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	938000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	integer
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	integer
	us-gaap	Net Income Loss NetIncomeLoss	-3451000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1084000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-1422000	usd
CY2024Q3	ZEOX	Working Capital Deficit WorkingCapitalDeficit	1909000	usd
CY2024Q3	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	179000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	154000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	71000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	156000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	250000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	310000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	770000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	795000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	274000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	222000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	496000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	573000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	18000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	31000	usd
	us-gaap	Depreciation Depreciation	56000	usd
	us-gaap	Depreciation Depreciation	90000	usd
CY2024Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
CY2023Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	127000	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	380000	usd
CY2024Q3	ZEOX	Equity In Nonmarketable Securities EquityInNonmarketableSecurities	145000	usd
CY2023Q4	ZEOX	Equity In Nonmarketable Securities EquityInNonmarketableSecurities	100000	usd
CY2024Q3	ZEOX	Reserve On Carrying Value Of Investment In Nonmarketable Securities ReserveOnCarryingValueOfInvestmentInNonmarketableSecurities	-145000	usd
CY2023Q4	ZEOX	Reserve On Carrying Value Of Investment In Nonmarketable Securities ReserveOnCarryingValueOfInvestmentInNonmarketableSecurities	-100000	usd
CY2023Q4	ZEOX	Equity In Nonmarketable Securities EquityInNonmarketableSecurities	100000	usd
CY2023Q4	ZEOX	Reserve On Carrying Value Of Investment In Nonmarketable Securities ReserveOnCarryingValueOfInvestmentInNonmarketableSecurities	-100000	usd
CY2024Q3	ZEOX	Reserve On Carrying Value Of Investment In Nonmarketable Securities ReserveOnCarryingValueOfInvestmentInNonmarketableSecurities	-145000	usd
CY2023Q4	ZEOX	Advances Payable AdvancesPayable	221000	usd
	ZEOX	Wroteoff Advances Payable WroteoffAdvancesPayable	221000	usd
CY2023Q4	ZEOX	Addtional Investment In Nonmarketable Securities AddtionalInvestmentInNonmarketableSecurities	45000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	667000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	667000	usd
CY2024Q3	ZEOX	Lab Equipment And Supplies Payables LabEquipmentAndSuppliesPayables	91000	usd
CY2023Q4	ZEOX	Lab Equipment And Supplies Payables LabEquipmentAndSuppliesPayables	407000	usd
CY2024Q3	ZEOX	Clinical Trial Payables ClinicalTrialPayables	624000	usd
CY2023Q4	ZEOX	Clinical Trial Payables ClinicalTrialPayables	675000	usd
CY2024Q3	ZEOX	Legal Fees Payables LegalFeesPayables	180000	usd
CY2023Q4	ZEOX	Legal Fees Payables LegalFeesPayables	479000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	105000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	81000	usd
CY2023Q4	ZEOX	Accrued Irs Penalty AccruedIrsPenalty	86000	usd
CY2024Q3	ZEOX	Accrued Commissions Payable AccruedCommissionsPayable	32000	usd
CY2023Q4	ZEOX	Accrued Commissions Payable AccruedCommissionsPayable	102000	usd
CY2024Q3	ZEOX	Construction Payables ConstructionPayables	9000	usd
CY2023Q4	ZEOX	Construction Payables ConstructionPayables	9000	usd
CY2024Q3	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	142000	usd
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	106000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1850000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2612000	usd
CY2024Q1	ZEOX	Abatement Of Penalties And Interest AbatementOfPenaltiesAndInterest	92000	usd
CY2024Q3	us-gaap	Convertible Debt ConvertibleDebt	725000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	725000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	51000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	68000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	674000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	657000	usd
CY2024Q3	us-gaap	Share Price SharePrice	0.001
CY2024Q1	us-gaap	Legal Fees LegalFees	20000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	20000	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	20000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	182500	shares
	ZEOX	Fair Value Of Nonvested Shares Granted FairValueOfNonvestedSharesGranted	325000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.78
	ZEOX	Fair Value Of Vested Shares FairValueOfVestedShares	-43000	usd
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	182500	shares
CY2024Q3	ZEOX	Fair Value Of Nonvested Shares FairValueOfNonvestedShares	282000	usd
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.78
	ZEOX	Unamortized Compensation UnamortizedCompensation	282000	usd
	ZEOX	Stock Options And Warrants StockOptionsAndWarrants	<p id="xdx_80A_ecustom--StockOptionsAndWarrants_zUE4jqJFztob" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 12 – <span id="xdx_82C_z07S28yqWC06">STOCK OPTIONS AND WARRANTS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued option securities under its Incentive Plan and warrants entitling the holder to purchase shares of its common stock at specified prices and for specified exercise periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Options:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company’s option activity for the nine months ended July 31, 2024 are presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zLDTybiye7qh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span id="xdx_8BC_zI2yoep5lfs7" style="display: none">Schedule of stock options and warrants</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/>Shares</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average<br/>Exercise Price</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining<br/>Contractual<br/>Term (years)</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/>Intrinsic Value</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">Outstanding at October 31, 2023</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIHoYIFHRJ8l" style="width: 9%; text-align: right" title="Number of shares, outstanding beginning balance">895,750</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYurCRaChg9i" style="width: 9%; text-align: right" title="Weighted-average exercise price, outstanding beginning balance">2.97</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zM0N1k5kQuCl" title="Remaining contractual term (years), outstanding beginning balance">5.67</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvA1jJHrG8Bf" style="width: 9%; text-align: right" title="Aggregate intrinsic value, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Number of shares, granted">622,538</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted-average exercise price, granted">2.52</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_900_ecustom--RemainingContractualTermYearsGranted_dtY_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5pDgETjVGKh" title="Remaining contractual term (years), granted">9.42</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_98C_ecustom--AggregateIntrinsicValueGranted_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="text-align: right" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Number of shares, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1016">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="text-align: right" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1020">-</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWuF8oskqpa5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired/forfeited">(190,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average exercise price, expired/forfeited">2.40</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--RemainingContractualTermYearsExpiredforfeited_dtY_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgI3JCO4Qt9j" title="Remaining contractual term (years), expired/forfeited">3.84</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td id="xdx_989_ecustom--AggregateIntrinsicValueExpiredforfeited_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1028">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Outstanding at July 31, 2024</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zihEebx5vof1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending balance">1,328,288</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsYusme0mN3j" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price outstanding ending balance">2.84</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYAjeLCENtoa" title="Remaining contractual term (years) outstanding ending balance">7.15</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdRYankp4YMf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value outstanding ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1036">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; text-align: left">Exercisable at July 31, 2024</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, exercisable">589,531</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, exercisable">3.26</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zmFPbK8zRm14" title="Remaining contractual term (years) outstanding, exercisable">5.65</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zeq44JbJhhlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended July 31, 2024, under its Incentive Plan, the Board approved the granting of options to certain employees, officers and directors to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20231101__20240731__srt--TitleOfIndividualAxis__srt--DirectorMember_pdd" title="Options granted">622,538</span> shares of its common stock. The options vest over various periods ranging from <span id="xdx_901_ecustom--VestingPeriod_c20231101__20240731__srt--TitleOfIndividualAxis__srt--DirectorMember" title="Vesting period">6 months to 3 years, expire five to ten years</span> from the date of grant and had an aggregate fair value of $<span id="xdx_90F_ecustom--OptionGrantDateFairValue_c20240731__srt--TitleOfIndividualAxis__srt--DirectorMember_pp0p0" title="Option grant date fair value">1,438,000</span> at the date of grant. The Company valued the options using a Black-Scholes option pricing model.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The assumptions used for the options granted during the period are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAssumptionsUsedForTheOptionsGrantedTableTextBlock_zUclGiMmdiNi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B6_z06yU2o6GEV9" style="display: none">Schedule of assumptions used for the options granted</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Exercise prices</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercise prices">2.00</span> - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise prices">4.50</span></p></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected dividends</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Expected volatility">156%</span>-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zNqdbAYzsZt3" title="Expected volatility">159</span></p></td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Risk free interest rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Risk free interest rate">4.20%</span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zkCaGxTbRiE7" title="Risk free interest rate">4.34</span></p></td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Expected life of options</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuy0zsmeiym4" title="Expected life of options">6.0</span></td> <td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zTms9vdHyEbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended July 31, 2024 and 2023, the Company amortized $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Stock compensation costs">692,000</span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20221101__20230731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Stock compensation costs">351,000</span>, respectively, of stock compensation costs associated with options issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There was approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20240731__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Unamortized compensation costs">1,545,000</span> of unamortized compensation associated with options outstanding as of July 31, 2024 that will be amortized over their respective remaining service periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Warrants:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company’s warrant activity for the nine months ended July 31, 2024 are presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfWarrantActivityTableTextBlock_zxxMOYfAkU27" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span id="xdx_8BA_zzilqsQq83S4" style="display: none">Schedule of warrant activity</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/>Shares</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average<br/>Exercise Price</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining<br/>Contractual<br/>Term (years)</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/>Intrinsic Value</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">Outstanding at October 31, 2023</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztM0DzF5T7ja" style="width: 9%; text-align: right" title="Number of shares, outstanding beginning balance">1,675,906</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zurrTz7jJhkj" style="width: 9%; text-align: right" title="Weighted-average exercise price, outstanding beginning balance">4.54</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGEjYTXIJFqi" title="Remaining contractual term (years), outstanding beginning balance">8.47</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXjdQkLMStnd" style="width: 9%; text-align: right" title="Aggregate intrinsic value, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1083">-</span></td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, granted">783,333</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted-average exercise price, granted">2.31</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90D_ecustom--RemainingContractualTermYearsGranted_dtY_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6Gn2VA4Tmm" title="Remaining contractual term (years), granted">10.00</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_98A_ecustom--AggregateIntrinsicValueGranted_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p0" style="text-align: right" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1091">-</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p0" style="text-align: right" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1099">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average exercise price, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td id="xdx_987_ecustom--AggregateIntrinsicValueExpiredforfeited_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Outstanding at July 31, 2024</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwAbfUuWubq" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending balance">2,459,239</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zb6NrF8lOhfg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price outstanding ending balance">3.83</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zl9X1wKhH8x2" title="Remaining contractual term (years) outstanding ending balance">8.43</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCwMMiNSbiBa" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value outstanding ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; text-align: left">Exercisable at July 31, 2024</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, exercisable">1,778,059</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, exercisable">4.39</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGbbG5wr4Eyk" title="Remaining contractual term (years) outstanding, exercisable">7.85</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1119">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zZ2RwkgWUtse" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 8, 2024, in connection with the Financing (see Note 11), the Company issued the Investor a cashless warrant to purchase an aggregate of <span id="xdx_90C_ecustom--NumberOfWarrantsToPurchase_c20240701__20240708__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Warrant to purchase">83,333</span> shares of common stock. The warrant is exercisable for $<span id="xdx_906_eus-gaap--WarrantExercisePriceIncrease_c20240701__20240708__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Exercise price">2.00</span> per share (the closing price of the Company’s common stock on the date of grant was $1.66), until the tenth anniversary date of the date of issuance. The exercise price and number of shares issuable upon exercise of the warrant are subject to adjustment to give effect to stock splits, stock dividends and other recapitalization events and the sale of shares at a purchase price less than the exercise price then in effect.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 11, 2024, our board of directors granted warrants to purchase <span id="xdx_906_ecustom--NumberOfWarrantsToPurchase_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Warrant to purchase">350,000</span> shares of our common stock (the “Warrants”) to each of two consultants to the Company, Skycrest Holdings, LLC and Greyt Ventures LLC (the “Consultants”). The Warrants vest in equal monthly installments over an eighteen (18) month period from the date of grant. Once vested, the Warrants are exercisable for a period of ten (<span id="xdx_901_ecustom--WarrantsExercisablePeriod_dtY_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziqIHm2aLzG4" title="Warrants exercisable period">10</span>) years from the date of grant at an exercise price of $<span id="xdx_90B_eus-gaap--WarrantExercisePriceIncrease_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Exercise price">2.35</span> per share (subject to adjustment for stock splits, stock dividends and similar recapitalization events). The Consultants, who are the controlling stockholders of the Company, were also accorded piggy-back registration rights under the Securities Act with respect to the shares of common stock issuable upon exercise of the Warrants. The Company valued the Warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Risk free interest rate">4.20%</span>, (2) term of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMfcTUYzmF84" title="Term">10</span> years, (3) expected stock volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Expected stock volatility">159%</span>, and (4) expected dividend rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Expected dividend rate">0%</span>. The grant date fair value of the total <span id="xdx_906_ecustom--NumberOfWarrantsGranted_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Number of warrants granted">700,000</span> Warrants granted was $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p0" title="Fair value of warrants granted">1,645,000</span>. The Company issued the foregoing securities pursuant to the exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended July 31, 2024 and 2023, the Company amortized $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20231101__20240731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p0" title="Stock compensation costs">1,640,000</span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20221101__20230731__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p0" title="Stock compensation costs">1,607,000</span>, respectively, of stock compensation costs associated with warrants issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There was approximately $3,631,000 of unamortized compensation associated with warrants outstanding as of July 31, 2024 that will be amortized over their respective remaining service periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All stock compensation expense is classified under general and administrative expenses in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2023	ZEOX	Deferred Revenue Invoiced Description DeferredRevenueInvoicedDescription	As of October 31, 2023, $101,000 of product inventory was invoiced and delivered reducing the deferred revenue amount to $399,000.
CY2024Q3	ZEOX	Initial Purchase Order InitialPurchaseOrder	403000	usd
CY2024Q3	ZEOX	Advances Advances	460000	usd
CY2023Q4	ZEOX	Advances Advances	399000	usd
CY2024Q3	ZEOX	Sales To Customers Not Yet Delivered SalesToCustomersNotYetDelivered	242000	usd
CY2023Q4	ZEOX	Sales To Customers Not Yet Delivered SalesToCustomersNotYetDelivered	98000	usd
CY2024Q3	us-gaap	Deferred Revenue DeferredRevenue	1105000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	497000	usd
CY2024Q3	ZEOX	Number Of Warrants To Purchase NumberOfWarrantsToPurchase	100000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0396	pure
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.47	pure
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024Q3	ZEOX	Fair Value Of Warrants Granted FairValueOfWarrantsGranted	185000	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	185000	usd
CY2024Q3	ZEOX	Number Of Shares Returned NumberOfSharesReturned	237602	shares
CY2024Q3	ZEOX	Value Of Shares Returned ValueOfSharesReturned	80000	usd

Files In Submission

Name	View Source	Status
0001829126-24-006296-index-headers.html	Edgar Link	pending
0001829126-24-006296-index.html	Edgar Link	pending
0001829126-24-006296.txt	Edgar Link	pending
0001829126-24-006296-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zeoscientifix_10q.htm	Edgar Link	pending
zeoscientifix_ex31-1.htm	Edgar Link	pending
zeoscientifix_ex32-1.htm	Edgar Link	pending
zeox-20240731.xsd	Edgar Link	pending
zeox-20240731_cal.xml	Edgar Link	unprocessable
zeox-20240731_def.xml	Edgar Link	unprocessable
zeox-20240731_pre.xml	Edgar Link	unprocessable
zeoscientifix_10q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
zeox-20240731_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZEOX
Zeo ScientifiX, Inc. Stock $zeox

2024 Q3 Form 10-Q Financial Statement

#000182912624006296 Filed on September 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZEOX Zeo ScientifiX, Inc. Stock $zeox

2024 Q3 Form 10-Q Financial Statement

#000182912624006296 Filed on September 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZEOX
Zeo ScientifiX, Inc. Stock $zeox